Log in to save to my catalogue

Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma

Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2575828513

Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

Metastatic uveal melanoma is an aggressive disease without an established standard treatment. In a randomized trial that evaluated tebentafusp, a soluble T-cell receptor bispecific protein, overall survival at 1 year was 73% among patients who received tebentafusp, as compared with 59% among those who received the investigator’s choice of therapy.

Alternative Titles

Full title

Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2575828513

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2575828513

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa2103485

How to access this item